Mohammad Isreb

Dr. Mohammad Isreb

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Colloid and Interface Science
Verified
Journal Article
Open access
BSBana Shriky
Bana Shriky
AKAdrian Kelly
Adrian Kelly
Mohammad IsrebMohammad Isreb
Mohammad Isreb
MBMaksims Babenko
Maksims Babenko
NMNajet Mahmoudi
Najet Mahmoudi
TGTim Gough
Tim Gough
Understanding structure-property relationships is critical for the development of new drug delivery systems. This study investigates the properties of Pluronic smart hydrogel formulations for future use as injectable controlled drug carriers. The smart hydrogels promise to enhance patient compliance, decrease side effects and reduce dose and frequency. Pharmaceutically, these systems are attractive due to their unique sol-gel phase transition in the body, biocompatibility, safety and injectability as solutions before transforming into gel matrices at body temperature. We quantify the structural changes of F127 systems under controlled temperature after flow, as experienced during real bodily injection. Empirical formulae combining the coupled thermal and shear dependency are produced to aid future application of these systems. Induced structural transitions measured in-situ by small angle x-ray and neutron scattering reveal mixed oriented structures that can be exploited to tailor the drug release profile.

14 February 2019 in Cancers
Verified
Journal Article
Open access
PDF file
YHYusuf Haggag
Yusuf Haggag
KMKyle Matchett
Kyle Matchett
RFRobert A Falconer
Robert A Falconer
Mohammad IsrebMohammad Isreb
Mohammad Isreb
JJJason Jones
Jason Jones
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (NPs). A modified double emulsion solvent evaporation technique was used to optimise the physicochemical properties of these peptide-loaded biodegradable NPs. The anti-cancer activity of peptide-loaded NPs was studied in vitro using Ran-expressing metastatic breast (MDA-MB-231) and lung cancer (A549) cell lines, and in vivo using Solid Ehrlich Carcinoma-bearing mice. The anti-metastatic activity of peptide-loaded NPs was investigated using migration, invasion and colony formation assays in vitro. A PEG-PLGA-nanoparticle encapsulating N-terminal peptide showed a pronounced antitumor and anti-metastatic action in lung and breast cancer cells in vitro and caused a significant reduction of tumor volume and associated tumor growth inhibition of breast cancer model in vivo. These findings suggest that the novel inhibitory peptides encapsulated into PEGylated PLGA NPs are delivered effectively to interact and deactivate Ran. This novel Ran-targeting peptide construct shows significant potential for therapy of breast cancer and other cancers mediated by Ran overexpression.

23 November 2016 in African Journal of Traditional, Complementary and Alternative Medicines
Verified
Journal Article
Open access
PDF file
SSSyed Muhammad Hassan Shah
Syed Muhammad Hassan Shah
FUFarhat Ullah
Farhat Ullah
SKShahzeb Khan
Shahzeb Khan
MSMuhammad Mukarram Shah Syed
Muhammad Mukarram Shah Syed
Mohammad IsrebMohammad Isreb
Mohammad Isreb
FABRICATION AND EVALUATION OF SMART NANOCRYSTALS OF ARTEMISININ FOR ANTIMALARIAL AND ANTIBACTERIAL EFFICACY

27 August 2022 in Polymers
Verified
Journal Article
Open access
PDF file
Mohammad IsrebMohammad Isreb
Mohammad Isreb
MCMarianiki Chalkia
Marianiki Chalkia
TGTim Gough
Tim Gough
RFRobert Forbes
Robert Forbes
Peter TimminsPeter Timmins
Peter Timmins
The viscoelastic nature of polymeric formulations utilised in drug products imparts unique thermomechanical attributes during manufacturing and over the shelf life of the product. Nevertheless, it adds to the challenge of understanding the precise mechanistic behaviour of the product at the microscopic and macroscopic level during each step of the process. Current thermomechanical and rheological characterisation techniques are limited to assessing polymer performance to a single phase and are especially hindered when the polymers are undergoing thermomechanical transitions. Since pharmaceutical processing can occur at these transition conditions, this study successfully proposes a thermomechanical characterisation approach combining both mechanical and rheological data to construct a comprehensive profiling of polymeric materials spanning both glassy and rubbery phases. This approach has been used in this study to assess the mechanical and rheological behaviour of heterogenous polymer blends of hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC) over a shearing rate range of 0.1–100 s−1 and a temperature range of 30–200 °C. The results indicate that HPC and HPMC do not appear to interact when mixing and that their mixture exhibits the mechanistic properties of the two individual polymers in accordance with their ratio in the mixture. The ability to characterise the behaviour of the polymers and their mixtures before, throughout, and after the glassy to rubbery phase transition by application of the combined techniques provides a unique insight towards a quality-by-design approach to this and other polymer-based solid dosage forms, designed with the potential to accelerate their formulation process through obviating the need for multiple formulation trials.

21 April 2022 in British Journal of Pharmacy
Verified
Journal Article
Open access
DADania Hussein Alhyari
Dania Hussein Alhyari
HSHelen Sheldrake
Helen Sheldrake
SKSriharsha Kantamneni
Sriharsha Kantamneni
Mohammad IsrebMohammad Isreb
Mohammad Isreb
SSShohreh Jafarinejad Soumehsaraei
Shohreh Jafarinejad Soumehsaraei
HKHarsha Kantamneni
Harsha Kantamneni
Gallic acid (GA) is known for its antioxidant activitywhichis restricted due to its low oral permeability. In this project the carboxylic group of (GA) was substitutedwith sulfonamide group and hydroxyl groups were methylated which resulted insignificantly (p<0.01) increased permeability of 3,4,5-trimethoxybenzenesulfonamide (TMBS) and 3,4,5-trihydroxybenzenesulfonamide (THBS) over GA, inParallel Artificial Membrane Permeability Assay studies with simulatedgastrointestinal fluids and Human intestinal epithelial cells HIEC-6 cells.Biochemical studies confirmed TMBS was O-demethylated by CYP2D6. THBS and GAhad increased antioxidant activity with increased concentration in DPPH assaywhile TMBS indicated lower activity at all tested concentration. Theantioxidant activity of TMBS was greater than GA in HIEC-6 cells which mainlyrelated to its O-demethylation by CYP2D6.

17 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MNMojgan Najafzadeh
Mojgan Najafzadeh
SJShohreh Jafarinejad
Shohreh Jafarinejad
SZSajad Falsafi Zadeh
Sajad Falsafi Zadeh
ABAdi Baumgartner
Adi Baumgartner
Mohammad IsrebMohammad Isreb
Mohammad Isreb
AWAndrew Wright
Andrew Wright
This study aimed to investigate the potential of Cord Blood Stem Cell-derived exosome vesicles (CBSC-EVs) in regulating cancer growth and preventing cellular damage. The study aimed to examine the effects of CBSC-EVs on CHL1 cancer cells and healthy fibroblasts. The study results reveal that CBSC-EVs have an anti-cancer/antioxidant effect on CHL1 cancer cells without inducing any toxic effects on healthy lymphocytes. Further analysis of CBSC-EVs revealed the presence of seven miRNAs (noncoding RNA molecules), including three from the Let 7 family, two from the Let 5 family, and two novel miRNAs. The function of the novel miRNAs was the main focus of the study. To assess the efficacy of CBSC-EVs, CHL1 cells (a type of malignant melanoma cell line) and human fibroblasts were grouped into different treatments. One group of those cell lines were treated with CBSC-EVs, and in the second group, the cells were transfected with either miRNA inhibitor Novel 1 (miRNA IN1) plus CBSC-EVs or miRNA inhibitor Novel 2 (miRNA IN2) and CBSC-EVs to knock down those novel miRNAs in the CBSC-EVs. Therefore, by comparing these groups, the function of novel miRNAs is more understandable. In this study, the Comet assay was employed to evaluate cancer cells' DNA damage and CCK8 to measure cell viability. The findings revealed that CBSC-EVs caused an increase in DNA damage in CHL1 cells compared to cells without treatment (p